Please note that some translations using Google Translate may not be accurately represented, and image captions and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result for using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
Dr. Goldberg received his PhD in 2008 from MIT, where he worked in the laboratory of Institute Professor Robert Langer. He subsequently pursued post-doctoral training under the supervision of Institute Professor Philip Sharp at MIT. In 2012, he became assistant professor of Microbiology and Immunobiology at Harvard Medical School and in the Department of Cancer Immunology at Dana-Farber Cancer Institute, where he works on the development and delivery of novel therapeutics.
Development and delivery of RNA therapeutics
The Goldberg Lab seeks to leverage the tools of drug delivery to manipulate the cell-extrinsic aspects of cancer in the tumor microenvironment. In particular, Dr. Goldberg recently joined our faculty to apply RNAi-based therapeutics to cancer immunotherapy. He has particular expertise in the development and delivery of cancer-specific siRNAs that target synthetic lethality and aberrant alternative splicing programs. Dr. Goldberg is credited with delivering the first single-agent synthetic lethal siRNA therapeutic in vivo – siRNA targeting Parp1 – for treatment of BRCA1-deficient ovarian cancer; more recently, he demonstrated that siRNA sequences specific to the cancer-expressed M2 isoform of pyruvate kinase induce apoptosis and tumor regression – independent of the cancer type or underlying genetic lesions – without affecting the viability of normal cells.
The focus of current studies includes targeting siRNA delivery to immune cells in vivo. Dr. Goldberg’s diverse training in chemistry, materials science, biotechnology, and molecular biology is combined with cutting-edge mRNA- and siRNA-based as well as nanoparticle-based therapeutic strategies, promising to yield innovative approaches to cancer immunotherapy.
Dana-Farber Cancer Institute450 Brookline AvenueSmith 770CBoston MA, 02215Get Directions